On The Pen GLP-1 News
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.
Episodes
172 episodes
Eli Lilly Earnings Call Q4 2025 Recap
This week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation G...
•
21:35
Once Monthly GLP-1 Injection? Pfizer Drops New Data
This week on On The Pen: The Weekly Dose, we break down Pfizer’s $10 billion bet on obesity medicine and whether it’s shaping up to be a smart move or a costly miss. We dig into newly released Phase 2b data from Pfizer’s once-monthly G...
•
21:39
A PCOS and Tirzepatide Trial. Finally
Can Zepbound treat PCOS? That's the question this clinical trial will seek to answer, and we cover it exclusively on this week's On The Pen podcast.
•
19:29
.png)
Over The Counter GLP-1 Prediction
In this episode of On The Pen: The Weekly Dose, Dave Knapp breaks down why the idea of over-the-counter GLP-1 medications isn’t radical speculation, it’s a pattern already in motion. Drawing on FDA signals, past regulatory precedent with Orlist...
•
21:02
%20(2).png)
GLP-1 PLUS Gastric Balloon for added Weight Loss!
Shantanu Gaur, CEO of Allurion, returns to the podcast to break down their swallowable inflatable weight loss balloon, how it works, who it is for, how much it is expected to cost, and when patients can realistically expect access.We ta...
•
31:48
.png)
GLP-1 Access, MariTide Data, and the Oprah Effect on Obesity Care
This week on On The Pen, we break down a rare FDA walk-back on GLP-1 safety labeling, major pharma signals coming out of JPM 2026, and the growing tension between patient access and legislative efforts that could restrict compounding. ...
•
27:54
.png)
Wegovy Pens Recalled & Wegovy Pill Launch
This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine.We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding ac...
•
26:11
Wegovy Pill Approved: First Ever GLP-1 Pill, As Good as Injections!
https://www.OTPLinks.com
•
29:14
GLP-1 Compound Legislation: States are the Next Battlefield w/ Sabina Hemme
Pharma Influence & Why Patient Voices MatterLobbying Power: Eli Lilly, Novo Nordisk, and Government AccessWhy GLP-1 Medication Access Is at RiskIntroducing Sabina Hemi & the Mission of GLP WinnerWhy Compounded GL...
•
59:05
Compounded Retatrutide? What the Judge Said
Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estima...
•
29:09
Retatrutide Weight Loss: How Much At Each Dose
https://www.otplinks.com0:00 Welcome & today’s focus: Retatrutide and “chasing the biggest number”1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping2:10 How Dave first heard about retatrutide (work trip...
•
50:24
Mounjaro vs. New Obesity Drugs: Why Wave-007 Is Stealing the Spotlight
Episode Timeline & Main Topics00:00 — Opening & Community Update• First week doing the podcast fully live thanks to the On The Pen community• Overview of why this week’s news is a major turning point in obesity medici...
•
34:00
GLP-1: New Metrics, New Molecules, New Prices
Topics We Cover:00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity03:00 – A new oral triple agonist shows record-setting absorption rates07:00 – Fractal Health’s Revita procedure: w...
•
29:39
Novo Nordisk Amycretin Shocker + Semaglutide Flopper
Follow Us Everywhere:https://www.otplinks.comSign up for Emails:https://www.obesity.news
•
36:28
Lower Cost Zepbound and Wegovy? TrumpRX Announcement Incoming
Exclusive OTP SavingsHTTPS://www.otplinks.com
•
45:58
Eli Lilly Earnings Call Recap: NEW GLP-1 GIP Peptide Announced!
EXCLUSIVE SAVINGS FOR YOU!www.OTPLinks.com
•
23:55
Retatrutide + Tirzepatide Grey Market Clampdown + 1 Billion GLP-1 Pills Incoming
GET EXCLUSIVE OTP SAVINGS!www.OTPLinks.com
•
29:41
HLTH 2025: Obesity Care Superstar Interviews
VIEW EXCLUSIVE OTP SAVINGS!http://otplinks.com/
•
49:48
TRUMP: Ozempic Will Soon be $150 in the US! Meet the Reporter Who Made Him Say It!
GET ACCESS TO OBESITY CARE AND MEDS AND SUPPORT OTP:https://lddy.no/1ndi6USE CODE: OTP25VISIT ALL OUR LINKS:https://linktr.ee/manonthemounjaro
•
29:33
Wegovy and Ozempic Users: FDA's Scathing Report on Major Novo Factory
Visit our Sponsors and check out EXCLUSIVE OTP Savings!www.OTPLinks.comwww.tryshed.com (use code OTP25 to save 25%)
•
27:44
Retatrutide News That Could Change Everything for GLP-1 Compounds
SUPPORT OUR WORK:OTPLinks.com💉 Story 1 — Fractyl Health’s One-and-Done Gene Therapy for ObesityFractyl Health just dropped preclinical results showing their GLP-1 + GIP gene therapy candidate RJVA-002 produced almost 30% weig...
•
40:26
